BiomarkersCholangiocarcinomaGenetics & Cancer
By Wayne Kuznar
New treatments are becoming available for patients with cholangiocarcinoma (bile duct cancer). Testing for specific biomarkers is crucial to ensure each patient receives the best available treatment for any associated biomarker.
CholangiocarcinomaFDA Approvals, News & Updates
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
CholangiocarcinomaInterview with the Advocates
An Interview with Stacie Lindsey, President, and Melinda Bachini, Advocacy Coordinator, Cholangiocarcinoma Foundation
View this slideshow to learn important facts about Gallbladder and bile duct cancer, including statistics, causes and symptoms.
The following section features a selection of patient stories submitted to the 2015 Hero of Hope™ Patient Award. These stories illustrate the range of extraordinary patient profiles submitted by patients, family members, friends, and healthcare providers.
Results 1 - 5 of 5